[Skip to Content]

Upstate Active Clinical Trials

Study Title:

PBD 01187: A Phase 2A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Varoglutamstat (PQ912) in Patients with Early Alzheimer’s Disease with a Stage Gate to Phase 2B (VIVAMIND)

What is the purpose of the study?

To evaluate the safety and efficacy of Varoglutamstat (PQ912) for early Alzheimer's disease

Upstate Institutional Review Board (IRB) Number:

1759872

Study/Protocol ID:

PBD 01187

Study Phase:

Phase 2A-B

Patient Age Group:

Adults

Principal Investigator:

Sharon A Brangman

What is involved if I participate?

  • How long is the study?
    76 weeks
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    No
  • What tests and procedures are involved?
    MRI, EEG, lumbar puncture

Where will the study take place?

Clinical Research Unit (CRU)

ClinicalTrials.Gov ID:

NCT03919162

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Colleen A Dillenbeck
Phone: 315-464-9014
Email: dillenco@upstate.edu

Return to Previous Page || Search Again

Top